GNMSF
Price
$237.28
Change
-$0.00 (-0.00%)
Updated
Oct 4 closing price
RIGL
Price
$15.63
Change
-$0.00 (-0.00%)
Updated
Oct 16 closing price
Ad is loading...

GNMSF vs RIGL

Header iconGNMSF vs RIGL Comparison
Open Charts GNMSF vs RIGLBanner chart's image
Genmab A/S
Price$237.28
Change-$0.00 (-0.00%)
Volume$625
CapitalizationN/A
Rigel Pharmaceuticals
Price$15.63
Change-$0.00 (-0.00%)
Volume$104.21K
CapitalizationN/A
View a ticker or compare two or three
GNMSF vs RIGL Comparison Chart
Loading...
GNMSF
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RIGL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
GNMSF vs. RIGL commentary
Oct 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GNMSF is a StrongSell and RIGL is a StrongSell.

COMPARISON
Comparison
Oct 18, 2024
Stock price -- (GNMSF: $224.83 vs. RIGL: $15.14)
Brand notoriety: GNMSF and RIGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GNMSF: 18% vs. RIGL: 38%
Market capitalization -- GNMSF: $15.44B vs. RIGL: $288.91M
GNMSF [@Biotechnology] is valued at $15.44B. RIGL’s [@Biotechnology] market capitalization is $288.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GNMSF’s FA Score shows that 0 FA rating(s) are green whileRIGL’s FA Score has 0 green FA rating(s).

  • GNMSF’s FA Score: 0 green, 5 red.
  • RIGL’s FA Score: 0 green, 5 red.
According to our system of comparison, RIGL is a better buy in the long-term than GNMSF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GNMSF’s TA Score shows that 4 TA indicator(s) are bullish while RIGL’s TA Score has 4 bullish TA indicator(s).

  • GNMSF’s TA Score: 4 bullish, 6 bearish.
  • RIGL’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, RIGL is a better buy in the short-term than GNMSF.

Price Growth

GNMSF (@Biotechnology) experienced а -4.03% price change this week, while RIGL (@Biotechnology) price change was -0.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.

Reported Earning Dates

RIGL is expected to report earnings on Aug 06, 2024.

Industries' Descriptions

@Biotechnology (+0.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GNMSF($15.4B) has a higher market cap than RIGL($289M). RIGL YTD gains are higher at: 7.793 vs. GNMSF (-29.442). GNMSF has higher annual earnings (EBITDA): 7.88B vs. RIGL (-4.93M). GNMSF has more cash in the bank: 15.7B vs. RIGL (49.1M). RIGL has less debt than GNMSF: RIGL (60.3M) vs GNMSF (1.02B). GNMSF has higher revenues than RIGL: GNMSF (19B) vs RIGL (130M).
GNMSFRIGLGNMSF / RIGL
Capitalization15.4B289M5,329%
EBITDA7.88B-4.93M-160,081%
Gain YTD-29.4427.793-378%
P/E Ratio18.55N/A-
Revenue19B130M14,615%
Total Cash15.7B49.1M31,976%
Total Debt1.02B60.3M1,690%
FUNDAMENTALS RATINGS
GNMSF vs RIGL: Fundamental Ratings
GNMSF
RIGL
OUTLOOK RATING
1..100
156
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
85
Overvalued
PROFIT vs RISK RATING
1..100
90100
SMR RATING
1..100
51100
PRICE GROWTH RATING
1..100
8037
P/E GROWTH RATING
1..100
91100
SEASONALITY SCORE
1..100
5018

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GNMSF's Valuation (67) in the null industry is in the same range as RIGL (85) in the Biotechnology industry. This means that GNMSF’s stock grew similarly to RIGL’s over the last 12 months.

GNMSF's Profit vs Risk Rating (90) in the null industry is in the same range as RIGL (100) in the Biotechnology industry. This means that GNMSF’s stock grew similarly to RIGL’s over the last 12 months.

GNMSF's SMR Rating (51) in the null industry is somewhat better than the same rating for RIGL (100) in the Biotechnology industry. This means that GNMSF’s stock grew somewhat faster than RIGL’s over the last 12 months.

RIGL's Price Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for GNMSF (80) in the null industry. This means that RIGL’s stock grew somewhat faster than GNMSF’s over the last 12 months.

GNMSF's P/E Growth Rating (91) in the null industry is in the same range as RIGL (100) in the Biotechnology industry. This means that GNMSF’s stock grew similarly to RIGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GNMSFRIGL
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
71%
Momentum
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
59%
Bearish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 7 days ago
66%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 22 days ago
67%
Bearish Trend 11 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
68%
Bullish Trend 2 days ago
76%
View a ticker or compare two or three
Ad is loading...
GNMSF
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
RIGL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME21.660.39
+1.83%
GameStop Corp
BTC.X67612.720000571.609400
+0.85%
Bitcoin cryptocurrency
TSLA221.331.76
+0.80%
Tesla
SPY582.302.52
+0.43%
SPDR® S&P 500® ETF Trust
AAPL231.78-2.07
-0.89%
Apple

GNMSF and

Correlation & Price change

A.I.dvisor indicates that over the last year, GNMSF has been loosely correlated with GMAB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if GNMSF jumps, then GMAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GNMSF
1D Price
Change %
GNMSF100%
-5.13%
GMAB - GNMSF
62%
Loosely correlated
-2.50%
RIGL - GNMSF
29%
Poorly correlated
+2.16%
ARCT - GNMSF
29%
Poorly correlated
-1.62%
VSTM - GNMSF
28%
Poorly correlated
+6.39%
AGIO - GNMSF
28%
Poorly correlated
+3.95%
More

RIGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, RIGL has been loosely correlated with NTLA. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if RIGL jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RIGL
1D Price
Change %
RIGL100%
+2.16%
NTLA - RIGL
45%
Loosely correlated
+5.43%
ALLO - RIGL
44%
Loosely correlated
+5.17%
PRME - RIGL
41%
Loosely correlated
+5.04%
INZY - RIGL
41%
Loosely correlated
-1.12%
CMPX - RIGL
41%
Loosely correlated
+3.66%
More